Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | PAK4 | O96013 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19922956 | 0.90 | HDAC6 (0.36) | HDAC6ARPDE5APDE4APDE1A | |
| SCHEMBL19922661 | 0.90 | HDAC6 (0.34) | HDAC6ARPDE5APDE4APDE1A | |
| SCHEMBL19922662 | 0.90 | HDAC6 (0.34) | HDAC6ARPDE5APDE4APDE1A | |
| SCHEMBL19922658 | 0.88 | HDAC6 (0.32) | HDAC6ARPDE5APDE4APDE1A | |
| SCHEMBL23875659 | 0.84 | AR (0.34) | ARPDE5APDE4APDE1APDE1B | |
| SCHEMBL23875464 | 0.82 | ABCB1 (0.34) | ARPDE5APDE4APDE1APDE1B | |
| SCHEMBL19922778 | 0.82 | AR (0.34) | HDAC6ARPDE5APDE4APDE1A | |
| Zagociguat SCHEMBL19922804 | 0.82 | AR (0.34) | HDAC6ARPDE5APDE4APDE1A | |
| Zagociguat SCHEMBL21332996 | 0.81 | AR (0.34) | HDAC6ARPDE5APDE4APDE1A | |
| SCHEMBL19922744 | 0.80 | PDE5A (0.36) | ARPDE5APDE4APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326761-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-11731977-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731977-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731977-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-3872080-B1 | FUSED BICYCLIC SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20220009937-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-13 | — | — | US | disclosed |
| US-20220009937-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-13 | — | — | US | disclosed |
| US-20210177846-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | TISENTO THERAPEUTICS INC. | 2021-06-17 | — | — | US | disclosed |
| EP-3507291-B1 | FUSED BICYCLIC SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3507291-B1 | FUSED BICYCLIC SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10858363-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10858363-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10472363-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472363-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190248794-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2019-08-15 | — | — | US | disclosed |
| US-20190248794-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2019-08-15 | — | — | US | disclosed |
| WO-2018045276-A1 | FUSED BICYCLIC SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180065971-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180065971-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180065971-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472363-B2 | SGC stimulators | GUCY1A2, PRKG1, GMPS | HDAC6 3283/4885AR 4543/4885PDE5A 12/4885 |
| US-10858363-B2 | SGC stimulators | GUCY1A2, PRKG1, GMPS | HDAC6 3283/4885AR 4543/4885PDE5A 12/4885 |
| US-20250326761-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | HDAC6 3283/4885AR 4543/4885PDE5A 12/4885 |
| US-20180065971-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | HDAC6 3283/4885AR 4543/4885PDE5A 12/4885 |
| US-20220009937-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | HDAC6 3283/4885AR 4543/4885PDE5A 12/4885 |
| US-20210177846-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | CS, COQ8A, GLS | HDAC6 2186/4885AR 4478/4885PDE5A 187/4885 |
| US-11731977-B2 | SGC stimulators | GUCY1A2, PRKG1, GMPS | HDAC6 3283/4885AR 4543/4885PDE5A 12/4885 |
| US-20190248794-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | HDAC6 3283/4885AR 4543/4885PDE5A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.